Table 3.
Univariate (UVA) and multivariate (MVA) analysis (Cox regression, forward stepwise) of clinical and dosimetric variables that potentially influence FEV1 decrease >3% in COPD patients
| COPD patients (N = 34) | ||
|---|---|---|
| Parameter | UVA | MVA |
| Gender | 0.382 | n.s. |
| Age | 0.179 | n.s. |
| Weight loss | 0.354 | n.s. |
| Karnofsky performance score | 0.043 | 0.048 |
| Tumor volume | 0.778 | n.s. |
| Tumor location | ||
| Lobe | 0.190 | n.s. |
| Peripheral or central | 0.653 | n.s. |
| Charlson comorbidity index | 0.264 | n.s. |
| Lung dose constraints | ||
| V20 ipsilateral lung | 0.369 | n.s. |
| V20 total lung | 0.349 | n.s. |
| V25 total lung | 0.955 | n.s. |
| Mean lung dose | 0.248 | n.s. |
CCI, Charlson comorbidity index; KPS, Karnofsky performance score; n.s., not significant.